» Articles » PMID: 34257575

Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software

Overview
Specialty Oncology
Date 2021 Jul 14
PMID 34257575
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

PD-L1 expression in non-small cell lung cancer (NSCLC) is predictive of response to immunotherapy, but scoring of PD-L1 immunohistochemistry shows considerable interobserver variability. Automated methods may allow more consistent and expedient PD-L1 scoring. We aimed to assess the technical concordance of PD-L1 scores produced using free open source QuPath software with the manual scores of three pathologists. A classifier for PD-L1 scoring was trained using 30 NSCLC image patches. A separate test set of 207 image patches from 69 NSCLC resection cases was used for comparison of automated and manual scores. Automated and average manual scores showed excellent correlation (concordance correlation coeffecient = 0.925), though automated scoring resulted in significantly more 1-49% scores than manual scoring ( = 0.012). At both 1% and 50% thresholds, automated scores showed a level of concordance with our 'gold standard' (the average of three pathologists' manual scores) similar to that of individual pathologists. Automated scoring showed high sensitivity (95%) but lower specificity (84%) at a 1% threshold, and excellent specificity (100%) but lower sensitivity (71%) at a 50% threshold. We conclude that our automated PD-L1 scoring system for NSCLC has an accuracy similar to that of individual pathologists. The detailed protocol we provide for free open source scoring software and our discussion of the limitations of this technology may facilitate more effective integration of automated scoring into clinical workflows.

Citing Articles

Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology.

Carretero-Barrio I, Pijuan L, Illarramendi A, Curto D, Lopez-Rios F, Estebanez-Gallo A Sci Rep. 2024; 14(1):24163.

PMID: 39406837 PMC: 11480438. DOI: 10.1038/s41598-024-75175-w.


Standardized Digital Image Analysis of PD-L1 Expression in Head and Neck Squamous Cell Carcinoma Reveals Intra- and Inter-Sample Heterogeneity with Therapeutic Implications.

Deuss E, Kurten C, Fehr L, Kahl L, Zimmer S, Kunzel J Cancers (Basel). 2024; 16(11).

PMID: 38893222 PMC: 11171694. DOI: 10.3390/cancers16112103.


Correlation Between ImageJ and Conventional Manual Scoring Methods for Programmed Death-Ligand 1 Immuno-Histochemically Stained Sections.

Al Taher R, Abbas M, Halahleh K, Sughayer M Technol Cancer Res Treat. 2024; 23:15330338241242635.

PMID: 38562094 PMC: 10989033. DOI: 10.1177/15330338241242635.


Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression.

Ligero M, Serna G, El Nahhas O, Sansano I, Mauchanski S, Viaplana C Cancer Res Commun. 2023; 4(1):92-102.

PMID: 38126740 PMC: 10782919. DOI: 10.1158/2767-9764.CRC-23-0287.


Breaking Barriers: AI's Influence on Pathology and Oncology in Resource-Scarce Medical Systems.

Vigdorovits A, Koteles M, Olteanu G, Pop O Cancers (Basel). 2023; 15(23).

PMID: 38067395 PMC: 10705335. DOI: 10.3390/cancers15235692.


References
1.
Chang S, Park H, Choi Y, Jang S . Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. J Pathol Transl Med. 2019; 53(6):347-353. PMC: 6877442. DOI: 10.4132/jptm.2019.09.29. View

2.
Humphries M, Bingham V, Sidi F, Craig S, McQuaid S, James J . Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. Cancers (Basel). 2020; 12(5). PMC: 7281311. DOI: 10.3390/cancers12051114. View

3.
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R . Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018; 6(1):8. PMC: 5778665. DOI: 10.1186/s40425-018-0316-z. View

4.
Naso J, Wang G, Banyi N, Derakhshan F, Shokoohi A, Ho C . Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma. Ann Diagn Pathol. 2020; 50:151590. DOI: 10.1016/j.anndiagpath.2020.151590. View

5.
Kapil A, Meier A, Zuraw A, Steele K, Rebelatto M, Schmidt G . Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies. Sci Rep. 2018; 8(1):17343. PMC: 6255873. DOI: 10.1038/s41598-018-35501-5. View